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Article Information  ABSTRACT 
Received: 17th Oct 2016  Oral route is presently the gold standard in the pharmaceutical industry where it is regarded as 
the safest, most economical and most convenient method of drug delivery resulting in highest 
patient compliance. Pediatric and geriatric patients find it difficult to swallow solid dosage 
forms like tablets. Mouth dissolving tablet that dissolve or disintegrate rapidly in oral cavity 
result in solution, is an ultimate remedy for this problem in addition they give pleasing mouth 
feeling. ODT has advantages such as patient compliance, quick onset of action, improved 
bioavailability. Domperidone tablet (ODT) gives relief from nausea, vomiting. This review 
gives us all information about pharmacokinetic, pharmacodynamic, uses, precautions, side 
effects of domperidone tablets 
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INTRODUCTION 
It is a drug developed by Janssen Pharmaceutical that acts as a 
peripherally selective antagonist of the dopamine D2 and D3 
receptors. It is administered orally, rectally, or intravenously. 
Domperidone is used to relieve nausea and vomiting; to 
increase the transit of food through the stomach (that is, as a 
prokinetic agent via increasing gastrointestinal peristalsis); and 
to promote lactation (breast milk production) by release of 
prolactin. It is also used in scientific research to study the 
biological function of dopamine, an important neurotransmitter 
and hormone, in the body. Domperidone is available in the 
form of tablets, orally disintegrating tablets suspension and 
suppositories. 
 
STRUCTURE OF DOMPERIDONE 
[1] 
MECHANISM OF ACTION  
Domperidone is a peripheral dopamine D2 and D3 receptor 
antagonist. It provides relief from nausea by blocking receptors 
at the chemoreceptor trigger zone (a location in the nervous 
system that mediates nausea) at the floor of the fourth ventricle 
(a location near the brain). It increases motility in the upper 
gastrointestinal tract to a moderate degree and increase lower 
esophageal sphincter pressure by blocking dopamine receptors 
the gastric antrum and the duodenum. It blocks dopamine 
receptors in the anterior pituitary gland increasing release of 
prolactin which in turn increases lactation. Domperidone may 
be more useful in some patients and cause harm ino    thers by 
way of the genetics of the person, such as polymorphisms in 
the drug transporter gene ABCB1 (which encodes P-
glycoprotein), voltage-gated potassium channelhERG/Kv11.1 
and the α1D—adrenoceptor[2]   
 
Dopamine receptors are G protein-coupled receptors that are 
prominent in the vertebrate central nervous system (CNS). 
Dopamine receptors are implicated in many neurological 
processes, including motivation, pleasure, cognition, memory, 
learning, and fine motor control, as well as modulation 
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of neuroendocrine signaling. Abnormal dopamine receptor 
signaling and dopaminergic nerve function is implicated 
in several neuropsychiatric disorders [1]. Thus, dopamine 
receptors are common neurologic drug 
targets; antipsychotics are often dopamine receptor 
antagonists while psychostimulants are typically indirect 
agonists of dopamine receptors.[3] 
 
Domperidone Tablet: Pharmacodynamics 
Domperidone tablet is a peripherally selective 
dopamine D2 and D3 receptor antagonist. It has no clinically 
significant interaction with the D1 receptor, unlike 
metoclopramide. The drug provides relief from nausea by 
blocking receptors at the chemoreceptor trigger zone (a 
location in the nervous system that mediates nausea) at the 
floor of the fourth ventricle (a location near the brain). It 
increases motility in the upper gastrointestinal tract to a 
moderate degree and increases lower esophageal 
sphincter pressure by blocking dopamine receptors in 
the gastric antrum and the duodenum. It blocks dopamine 
receptors in the anterior pituitary gland increasing release 
of prolactin which in turn increases lactation. [4] 
 
Effects on prolactin levels 
A single 20 mg oral dose of domperidone has been found to 
increase mean serum prolactin levels (measured 90 minutes 
post-administration) in non-lactating women from 8.1 ng/mL to 
110.9 ng/mL (a 13.7-fold increase).This was similar to the 
increase in prolactin levels produced by a single 20 mg oral 
dose of metoclopramide (7.4 ng/mL to 124.1 ng/mL; 16.7-fold 
increase).After two weeks of chronic administration 
(30 mg/day in both cases), the increase in prolactin levels 
produced by domperidone was reduced (53.2 ng/mL; 6.6-fold 
above baseline), but the increase in prolactin levels produced 
by metoclopramide, conversely, was heightened (179.6 ng/mL; 
24.3-fold above baseline). 
This indicates that acute and chronic administration of both 
domperidone and metoclopramide is effective in increasing 
prolactin levels, but that there are differential effects on the 
secretion of prolactin with chronic treatment.The mechanism of 
the difference is unknown.The increase in prolactin levels 
observed with the two drugs was, as expected, much greater in 
women than in men. This appears to be due to the 
higher estrogen levels in women, as estrogen stimulates 
prolactin secretion. 
For comparison, normal prolactin levels in women are less than 
20 ng/mL, prolactin levels peak at 100 to 300 ng/mL 
at parturition in pregnant women, and in lactating women, 
prolactin levels have been found to be 90 ng/mL at 10 days 
postpartum and 44 ng/mL at 180 days postpartum[5] 
 
Effects on TSH levels 
Along with prolactin, domperidone has, to a lesser extent, been 
found to increase the secretion of thyroid-stimulating 
hormone (TSH), even in patients with hypothyroidism. A 
single 4 mg intravenous dose of domperidone produced peak 
TSH levels of 1.9-fold above baseline and peak prolactin levels 
of 23-fold above baseline (which occurred at 30 minutes post-
administration) in women with hypothyroidism.Levels of TSH 
and prolactin decreased to 1.6-fold and 17-fold above baseline, 
respectively, at 120 minutes post-administration[6] 
 
Domperidone Tablet:  Pharmacokinetic Properties 
Absorption 
Domperidone is rapidly absorbed after oral administration, with 
peak plasma concentrations occurring at approximately 1 hr 
after dosing. The Cmax and AUC values of domperidone 
increased proportionally with dose in the 10 mg to 20 mg dose 
range. A 2- to 3-fold accumulation of domperidone AUC was 
observed with repeated four times daily (every 5 hr) dosing of 
domperidone for 4 days.The low absolute bioavailability of 
oral domperidone (approximately 15%) is due to an extensive 
first-pass metabolism in the gut wall and liver. Although 
domperidone's bioavailability is enhanced in normal subjects 
when taken after a meal, patients with gastro-intestinal 
complaints should take domperidone 15-30 minutes before a 
meal. Reduced gastric acidity impairs the absorption of 
domperidone. Oral bioavailability is decreased by prior 
concomitant administration of cimetidine and sodium 
bicarbonate. The time of peak absorption is slightly delayed 
and the AUC somewhat increased when the oral drug is taken 
after a meal. 
 
Distribution 
Oral domperidone does not appear to accumulate or induce its 
own metabolism; a peak plasma level after 90 minutes of 21 
ng/ml after two weeks oral administration of 30 mg per day 
was almost the same as that of 18 ng/ml after the first dose. 
Domperidone is 91-93% bound to plasma proteins. Distribution 
studies with radiolabelled drug in animals have shown wide 
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tissue distribution, but low brain concentration. Small amount 
of drug crosses the placenta in rats. 
 
Metabolism 
Domperidone undergoes rapid and extensive hepatic 
metabolism by hydroxylation and N-dealkylation. In vitro 
metabolism experiments with diagnostic inhibitors revealed 
that CYP3A4 is a major form of cytochrome P-450 involved in 
the N-dealkylation of domperidone, whereas CYP3A4, 
CYP1A2 and CYP2E1 are involved in domperidone aromatic 
hydroxylation. 
 
Excretion 
Urinary and faecal excretions amount to 31 and 66% of the oral 
dose respectively. The proportion of the drug excreted 
unchanged is small (10% of faecal excretion and approximately 
1% of urinary excretion). The plasma half-life after a single 
oral dose is 7-9 hours in healthy subjects but is prolonged in 
patients with severe renal insufficiency. With oral 
administration, domperidone is extensively metabolized in the 
liver (almost exclusively by CYP3A4/5, though minor 
contributions by CYP1A2, CYP2D6, and CYP2C8 have also 
been reported)and in the intestines.[5] Due to the marked first-
pass effect via this route, the oral bioavailability of 
domperidone is low (13–17%); conversely, its bioavailability is 
high via intramuscular injection (90%). The terminal half-life 
of domperidone is 7.5 hours in healthy individuals, but can be 
prolonged to 20 hours in people with severe renal 
dysfunction.All of the metabolites of domperidone are inactive 
as D2 receptor ligands.The drug is a substrate for the P-
glycoprotein (ABCB1) transporter, and animal studies suggest 
that this is the reason for the low central nervous system 
penetration of domperidone.[7] 
 
Domperidone Tablet: Uses 
The uses or indications of domperidone vary between nations. 
For instance, in Italy it is used in the treatment of 
gastroesophageal reflux disease and in Canada, the drug is 
indicated in upper gastrointestinal motility disorders and to 
prevent gastrointestinal symptoms associated with the use of 
dopamine agonist antiparkinsonian agents. In the United States, 
domperidone is not currently a legally marketed human drug 
and it is not approved for sale in the U.S. On June 7, 2004, 
FDA issued a public warning that distributing any 
domperidone-containing products is illegal. In the United 
Kingdom, domperidone is only indicated for the treatment of 
nausea and vomiting and the treatment duration is usually 
limited to 1 week.Nausea and vomitingThere is some evidence 
that domperidone has antiemetic activity. It is recommended in 
the Canadian Headache Society's guidelines for treatment of 
nausea associated with acute migraine. 
 
a. Gastroparesis 
It is a medical condition characterised by delayed emptying of 
the stomach when there is no mechanical gastric outlet 
obstruction. Its cause is most commonly idiopathic, a diabetic 
complication or a result of abdominal surgery. The condition 
causes nausea, vomiting, fullness after eating, early satiety 
(feeling full before the meal is finished), abdominal pain and 
bloating.Domperidone may be useful in diabetic and idiopathic 
gastroparesis.However, increased rate of gastric emptying 
induced by drugs like domperidone does not always correlate 
(equate) well with relief of symptoms.[8] 
 
b. Parkinson's disease 
Parkinson's disease is a chronic neurological condition where a 
decrease in dopamine in the brain leads to rigidity (stiffness of 
movement), tremor and other symptoms and signs. Poor 
gastrointestinal function, nausea and vomiting is a major 
problem for people with Parkinson's disease because most 
medications used to treat Parkinson's disease are given by 
mouth. These medications, such as levodopa can cause nausea 
as a side effect.  
 
Furthermore, anti-nausea drugs, such as metoclopramide, 
which do cross the blood–brain barrier may worsen the extra-
pyramidal symptoms of Parkinson's disease.Domperidone can 
be used to relieve gastrointestinal symptoms in Parkinson's 
disease, because, even though it blocks dopamine receptors 
(which would be expected to worsen Parkinson's disease), it 
does not cross the blood–brain barrier (the barrier between the 
blood circulation of the brain and the rest of the body). In 
addition to this, domperidone may enhance the bioavailability 
(effect) of levodopa (one of the main treatments in Parkinson's 
disease). 
 
Although these features make domperidone a useful drug in 
Parkinson's disease, caution is needed due to the cardiotoxic 
side effects of domperidone especially when given 
intravenously, in elderly people and in high doses (> 30 mg per 
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day). A clinical sign of domperidone's potential toxicity to the 
heart is the prolongation (lengthening) of the QT interval (a 
segment of the heart's electrical pattern).Functional 
dyspepsiaDomperidone may be used in functional dyspepsia in 
both adults and children.[9] 
 
c. Nausea and vomiting 
There is some evidence that domperidone 
has antiemetic activity. It is recommended in the Canadian 
Headache Society's guidelines for treatment of nausea 
associated with acute migraine.  
 
[10] 
Domperidone Tablet: Side effects 
a. Penetration of immature blood brain barrier 
In Britain a legal case involved the death of two children of a 
mother whose three children had all had hypernatraemia. She 
was charged with poisoning the children with salt. One of the 
children, who was born at 28 weeks gestation with respiratory 
complications and had a fundoplication for gastroesophageal 
reflux and failure to thrive was prescribed domperidone An 
advocate for the mother suggested the child may have suffered 
neuroleptic malignant syndrome . as a side effect of 
domperidone due to the drug crossing the child's immature 
blood brain barrier.[11] 
 
b. Cardiac side effects 
UK drug regulatory authorities (MHRA) have issued the 
following restriction on domperidone due to increased risk of 
adverse cardiac effects. "Domperidone (Motilium) is associated 
with a small increased risk of serious cardiac side effects. Its 
use is now restricted to the relief of nausea and vomiting and 
the dosage and duration of use have been reduced. It should no 
longer be used for the treatment of bloating and heartburn. 
Domperidone is now contraindicated in those with underlying 
cardiac conditions and other risk factors. Patients with these 
conditions and patients receiving long-term treatment with 
domperidone should be reassessed at a routine appointment, in 
light of the new advice". 
 
c.Other side effects 
Due to D2 receptor blockade, domperidone causes 
hyperprolactinemia. Hyperprolactinemia can suppress the 
secretion of gonadotropin-releasing hormone (GnRH) from the 
hypothalamus, in turn suppressing the secretion of follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) and 
resulting in hypogonadism (low sex hormone (e.g., 
testosterone, estradiol) levels).As such, male patients may 
experience low libido, erectile dysfunction [12]          
                                                                                   
 DOMPERIDON SCHEDULE H DRUG 
 Schedule H is a class of prescription drugs in India appearing 
as an appendix to the Drugs and Cosmetics Rules, 
1945 introduced in 1945. These are drugs which cannot be 
purchased over the counter without the prescription of a 
qualified doctor. The manufacture and sale of all drugs are 
covered under the Drugs and Cosmetics Act and Rules. It is 
revised at times based on the advice of the Drugs Technical 
Advisory Board, part of the Central Drugs Standard Control 
Organization in the Ministry of Health and Family Welfare 
domperidone is used to relieve feelings of sickness (nausea) or 
being sick (vomiting). Feeling sick can be a common symptom, 
but it may be due to a number of different causes. You will 
only be recommended an anti-emetic like domperidone if the 
cause of your sickness is known.Domperidone works by 
helping to move the food in your stomach through your 
digestive system more quickly. This helps to stop you from 
feeling sick. [13] 
 
DOMPERIDONE Tablet: Dose 
Domperidone is an anti-emetic which can stop you feeling sick. 
Each tablet contains 10mg domperidone as domperidone 
maleate. Domperidone is used to treat: nausea and vomiting 
complaints of the stomach, which occur with delayed emptying 
of the stomach. This can result in symptoms such as feeling full 
(during or just after eating), bloating, belching, nausea, 
heartburn and stomach ache. These tablets have been 
prescribed for you by a doctor. Take them exactly as he or she 
has told you. Please read the label carefully. Domperidone 
should be used at the lowest effective dose in adults and 
children. The tablets should be swallowed whole with a 
sufficient quantity of liquid (e.g. one glass of water).  
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Adults and adolescents  
The usual dose for the treatment is 1 to 2 tablets taken 3 to 4 
times a day before meals. Do not take more than 8 tablets 
(80mg) in 24 hours.  
 
Infants and Children  
Weighing less than 35kg (5 stone) should not take these tablets. 
The usual dose for the treatment is 0.25 0.5mg per kg 
bodyweight taken 3 to 4 times a day before meals. Your 
pharmacist may be able to help you if you are not sure.  
 
People with kidney problems  
Your doctor may tell you to take a lower dose or take the 
medicine less often. Your doctor may advise you to take your 
medicine in a different way, so you should always follow your 
doctor s advice about how and when to take your medicine and 
always read the label. If you feel that the effect of 
Domperidone 10mg Tablets is too strong or too weak, talk to 
your doctor or pharmacist. If your complaint shows no 
improvement after 28 days while taking Domperidone 10mg 
Tablets, consult your doctor to see if you need to go on taking 
this medicine. [14] 
 
PRECAUTIONS 
 Like all medicines, Domperidone 10mg Tablets can have 
sideeffects Tell your doctor your medical history, especially of: 
history of breast cancer, allergies. Limit your intake of 
alcoholic beverages. This medication should be used only if 
clearly needed during pregnancy. Discuss the risks and benefits 
with your doctor. Domperidone passes into breast milk. 
 
DRUG INTERACTIONS 
 Because this medication enhances movement in the digestive 
tract, it may affect the absorption and action of other 
medications. Therefore, it is important to tell your doctor of 
any nonprescription or prescription medication you may take, 
especially of: MAOIs (e.g., furazolidone, phenelzine, 
selegiline, tranylcypromine). Do not start or stop any medicine 
without doctor or pharmacist approval. 
 
OVERDOSE 
If overdose is suspected, contact your local poison control 
center or emergency room immediately. US residents can call 
the US national poison hotline at 1-800-222-1222. Canadian 
residents should call their local poison control center directly. 
Symptoms of overdose may include drowsiness, dizziness, 
confusion, twitching, muscle rigidity, and irregular heartbeat. 
[15]       
                   
CONCLUSION 
This review gives us all detailed knowledge about 
Domperidone tablet and concludes that it is considered better 
as an antiemetic in children. 
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